(Reuters) – Annovis Bio said on Monday that its Alzheimer’s treatment failed to meet the main goals of a mid-stage trial.
Annovis plans to conduct a late-stage trial based on results of this trial.
(This story has been corrected to say that Annovis’ drug failed to meet main goal of mid-stage trial in the headline and paragraph 1. An earlier version of the story said the drug had significantly improved cognition in Alzheimer’s disease patients. Also, drops paragraph 2)
(Reporting by Christy Santhosh; Editing by Vijay Kishore)
Brought to you by www.srnnews.com
